Volume 73, Issue 5, Pages (March 2008)

Slides:

Advertisements

Similar presentations

Renal Stress Testing in the Assessment of Kidney Disease Lakhmir S. Chawla, Claudio Ronco Kidney International Reports Volume 1, Issue 1, Pages (May.

Advertisements

Management of IgA nephropathy: Evidence-based recommendations

Beta blockers in the management of chronic kidney disease

Isolated Systolic Hypertension: An Update After SPRINT

Volume 84, Issue 2, Pages (August 2013)

Combination therapy with ACE inhibitors and angiotensin II receptor blockers in chronic renal disease: New therapeutic world beyond blood pressure reduction

Diabetic Kidney Disease: An ACEI (or an ARB) in the Hole

Viper venom for diabetic nephropathy

Anemia management in chronic kidney disease

Mitchell H. Rosner, W. Kline Bolton Kidney International

Volume 83, Issue 3, Pages (March 2013)

Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure Steven Fishbane, Nobuyuki Miyawaki Kidney International

Francesco Locatelli, Lucia Del Vecchio, Simeone Andrulli, Sara Colzani

Membranous nephropathy: When and how to treat

Viper venom for diabetic nephropathy

Status of chronic kidney disease prevention programs: International Federation of Kidney Foundation Members 2005/2007 Joanna M. Smith, Susan A. Mott,

Reassessment of the care of the patient with chronic kidney disease

Volume 80, Issue 10, Pages (November 2011)

Propofol as a panacea for acute kidney injury?

Volume 81, Issue 7, Pages (April 2012)

Audit-based education: a potentially effective program for improving guideline achievement in CKD patients Moniek C.M. de Goeij, Joris I. Rotmans Kidney.

Volume 80, Issue 9, Pages (November 2011)

Jeffrey C. Fink, Glenn M. Chertow Kidney International

Volume 94, Issue 3, Pages (September 2018)

Tubular biomarkers to assess progression of diabetic nephropathy

Volume 84, Issue 1, Pages (July 2013)

Comorbidity and confounding in end-stage renal disease

Steven J. Rosansky, Richard J. Glassock Kidney International

Volume 74, Issue 3, Pages (August 2008)

Volume 70, Issue 11, Pages (December 2006)

Volume 72, Issue 12, Pages (December 2007)

Volume 73, Issue 7, Pages (April 2008)

Volume 86, Issue 2, Pages (August 2014)

Volume 87, Issue 2, Pages (February 2015)

Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotension A. Davenport, C. Cox, R. Thuraisingham Kidney.

Correction to "Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate.

Volume 76, Issue 5, Pages (September 2009)

Cardiac medications and their association with cardiovascular events in incident dialysis patients: Cause or effect? Areef Ishani, Charles A. Herzog,

Volume 73, Issue 12, Pages (June 2008)

Volume 82, Issue 1, Pages 3-4 (July 2012)

David M. Charytan, John P. Forman Kidney International

Volume 76, Issue 6, Pages (September 2009)

Volume 85, Issue 3, Pages (March 2014)

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

The future of renoprotection: Frustration and promises

Volume 84, Issue 5, Pages (November 2013)

Nephrology Crossword: Glomerulonephritis

Isolated Systolic Hypertension: An Update After SPRINT

A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease S. Susan Hedayati, Venkata Yalamanchili,

Volume 76, Issue 1, Pages 6-7 (July 2009)

Comparative Superiority of ACE Inhibitors Over Angiotensin Receptor Blockers for People With CKD: Does It Matter? Dimitris Mavridis, PhD American Journal.

Volume 78, Issue 4, Pages (August 2010)

Volume 87, Issue 5, Pages (May 2015)

Volume 73, Issue 9, Pages (May 2008)

Volume 81, Issue 7, Pages (April 2012)

Carmine Zoccali, Francesca Mallamaci Kidney International

Volume 80, Issue 10, Pages (November 2011)

This Month in AJKD American Journal of Kidney Diseases

Volume 64, Issue 4, Pages (October 2003)

Is complement a target for therapy in renal disease?

Volume 74, Issue 9, Pages (November 2008)

Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: Pathophysiology and indications

(A) Distribution of CsA nephrotoxicity lesions according to antihypertensive treatment and CsA C2 levels. (A) Distribution of CsA nephrotoxicity lesions.

Unadjusted odds ratio of death at 6 mo for medications (β blockers [BBL], angiotensin-converting enzyme inhibitors [ACEI]/angiotensin receptor blockers.

Friends, social networks, and progressive chronic kidney disease

Combination angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB) reduced risk for renal end point versus ACEI or ARB. Effect.

Proteinuria and hypertension with tyrosine kinase inhibitors

Epidemiologic data of renal diseases from a single unit in China: Analysis based on 13,519 renal biopsies Lei-Shi Li, Zhi-Hong Liu Kidney International

Renin-angiotensin-aldosterone-system inhibition is safe in the preoperative period surrounding carotid endarterectomy Andrea M. Steely, MD, Peter W.

Presentation transcript:

Volume 73, Issue 5, Pages 531-532 (March 2008) Journal Club Kidney International Volume 73, Issue 5, Pages 531-532 (March 2008) DOI: 10.1038/ki.2008.2 Copyright © 2008 International Society of Nephrology Terms and Conditions

Quality assessment. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium-channel blocker; Combi, combination therapy. Kidney International 2008 73, 531-532DOI: (10.1038/ki.2008.2) Copyright © 2008 International Society of Nephrology Terms and Conditions

HIF-1α in renal biopsies from patients with chronic kidney disease. nl HIF-1α in renal biopsies from patients with chronic kidney disease. nl., normal control kidney; DN, diabetic nephropathy; gl., glomerulus. Asterisk indicates area with nodular sclerosis. Kidney International 2008 73, 531-532DOI: (10.1038/ki.2008.2) Copyright © 2008 International Society of Nephrology Terms and Conditions